» Articles » PMID: 11402860

A Single Amino Acid Change at Leu-188 in the Reverse Transcriptase of HIV-2 and SIV Renders Them Sensitive to Non-nucleoside Reverse Transcriptase Inhibitors

Overview
Journal Arch Virol
Specialty Microbiology
Date 2001 Jun 14
PMID 11402860
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are selective for human immunodeficiency virus type 1 (HIV-1) and generally not effective on HIV-2 or simian immunodeficiency virus (SIV). Only SIVagm was found to be sensitive to NNRTIs. When the amino acid differences in RT between SIVmac and SIVagm were compared with the known amino acid substitutions of NNRTI-resistance variants of HIV-1, we came to consider that the amino acid residue Leu-188 of HIV-2 and SIVmac might be related to their resistance to NNRTIs. To test this hypothesis, we substituted Leu-188 to Cys or Tyr in HIV-2 and SIVmac, and examined sensitivity of the mutant molecular clones to NNRTIs. The L188Y mutant of HIV-2 became completely sensitive to delavirdine and efavirenz, while that of SIVmac was also significantly sensitive to these NNRTIs. We further isolated NNRTI-resistant variants from these mutant viruses and determined amino acid substitutions in RT. The roles of the observed substitutions in NNRTI-resistance were further confirmed by site-directed mutagenesis. Our study reveals the crucial role of L188 in the natural resistance of HIV-2 and SIVmac to NNRTIs. Furthermore, the observed substitutions in RT of HIV-2 and SIVmac support the common mechanism of action of NNRTIs against HIV-1, HIV-2 and SIV.

Citing Articles

Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds.

Moranguinho I, Taveira N, Bartolo I Int J Mol Sci. 2023; 24(6).

PMID: 36982978 PMC: 10053740. DOI: 10.3390/ijms24065905.


Temporal trends in treatment outcomes for HIV-1 and HIV-2-infected adults enrolled in Côte d'Ivoire's national antiretroviral therapy program.

Auld A, Ekra K, Shiraishi R, Tuho M, Kouakou J, Mohamed F PLoS One. 2014; 9(5):e98183.

PMID: 24866468 PMC: 4035349. DOI: 10.1371/journal.pone.0098183.


Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

Peterson K, Jallow S, Rowland-Jones S, I de Silva T AIDS Res Treat. 2011; 2011:463704.

PMID: 21490779 PMC: 3065912. DOI: 10.1155/2011/463704.


The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.

Xu H, Quan Y, Schader S, Oliveira M, Bar-Magen T, Wainberg M Antimicrob Agents Chemother. 2010; 54(6):2401-8.

PMID: 20308384 PMC: 2876396. DOI: 10.1128/AAC.01795-09.


Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.

Dang Z, Lai W, Qian K, Ho P, Lee K, Chen C J Med Chem. 2009; 52(23):7887-91.

PMID: 19526990 PMC: 2788670. DOI: 10.1021/jm9004253.